Table 1

Variable	Disease	Category	Estimate	Count
Proportion	lcSSc	Female:Male	18.0:1	18:1
Proportion	dcSSc	Female:Male	1.2:1	6:5

Severity Index	lcSSc		7.00 ± 0.78	18
Severity Index	dcSSc		7.18 ± 0.91	11

Modified Rodnan	lcSSc		9.05 ± 1.29	19
Skin Score	dcSSc		22.82 ± 2.82	11

Age	lcSSc		58.53 ± 2.50 yr	19
Age	dcSSc		49.64 ± 3.17 yr	11

Duration	lcSSc		10.68 ± 2.68 yr	19
Duration	dcSSc		2.91 ± 0.48 yr	11

Lung
ILD	lcSSc		47.4 ± 11.5 %	19
	dcSSc		63.6 ± 14.5 %	11

Putative PAH	lcSSc		47.4 ± 11.5 %	19
Putative PAH	dcSSc		36.4 ± 14.5 %	11

FVC Predicted	lcSSc		86.6 ± 4.5 %	18
FVC Predicted	dcSSc		73.4 ± 6.5 %	11

DLCO	lcSSc		63.1 ± 4.9 %	19
Predicted	dcSSc		64.8 ± 8.3 %	10

Telangiectasia	lcSSc		17.6 ± 9.2 %	17
	dcSSc		20.0 ± 12.6 %	10

Digits
Raynaud’s	lcSSc		100 %	18
	dcSSc		100 %	11

Active digital ulcers	lcSSc		35.3 ± 11.6 %	17
Active digital ulcers	dcSSc		30.0 ± 14.5 %	10

No. of digits with	lcSSc		0.71 ± 0.28	17
Active digital ulcers	dcSSc		0.88 ± 0.48	9

Contracture of	lcSSc		41.2 ± 11.9 %	17
phalanges	dcSSc		63.6 ± 14.5 %	11

Autoantibodies
ACA positive	lcSSc		15.8 ± 8.4%	19
ACA positive	dcSSc		0 %	11

ANA positive	lcSSc		84.2 ± 8.4%	19
ANA positive	dcSSc		90.1 ± 8.7%	11

Scl-70 positive	lcSSc		15.8 ± 8.4%	19
Scl-70 positive	dcSSc		72.7 ± 13.4%	11

Treatment
Methotrexate	lcSSc		0 %	19
	dcSSc		18.2 ± 11.6 %	11

Cyclophosphamide	lcSSc		0 %	19
	dcSSc		45.5 ± 15.0 %	11
Except where indicated otherwise, values are the mean ± SE.

Table 1: Demographics.